Tracking hemolytic syndrome risk in CLL patients on venetoclax
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial checks the risk of hemolytic syndrome (a condition where your body's immune system destroys its own red blood cells) in people with chronic lymphocytic leukemia (CLL) who are being treated with venetoclax along with other targeted drugs. It aims to make treatment safer by closely monitoring for this side effect.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic lymphocytic leukemia (CLL) or a related lymphoma.
- Your doctor has decided you need treatment based on standard guidelines.
- You are eligible to take venetoclax together with a Bruton's tyrosine kinase inhibitor (like ibrutinib) or obinutuzumab.
- This could be your first treatment or a treatment after the disease has come back.
- You do not have active, uncontrolled infections.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why chronic lymphocytic leukemia may stop responding after a medicine called venetoclax. By analyzing tumor samples, researchers hope to better understand resistance and guide future treatment options.
This trial tests how well venetoclax (a targeted pill for CLL) works in people whose CLL has come back or hasn’t responded. It also closely tracks early changes in the CLL cells to better understand what happens during treatment.
This trial tests giving venetoclax to people with CLL who are already taking a BTK inhibitor and have stable disease. The goal is to see if adding venetoclax can help eliminate any remaining CLL cells.
This trial tests two different drug combinations (venetoclax with obinutuzumab or with acalabrutinib) to see how they affect the risk of tumor lysis syndrome in people with untreated CLL or SLL. It may help find the safest and most effective way to start treatment.
This study looks at how the environment inside lymph nodes changes in people with chronic lymphocytic leukemia (CLL) who are being treated with venetoclax. It may help doctors better understand what’s happening in the body during treatment and improve future care.
This Phase 2 trial tests a combination of three medicines to treat chronic lymphocytic leukemia (CLL) that has not been treated before and where the goal is to achieve very low remaining disease. It may help some people stay in remission longer, but eligibility depends on your age, organ function, and prior treatments.
Hear when a new Chronic Lymphoid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.